Phase II clinical trials of the drug for the prevention and treatment of coronavirus infection have begun in the country MIR-19 on patients with coronavirus, the head of the Federal Medical and Biological Agency (FMBA) of Russia Veronika Skvortsova said on the air of the Dock-tok program on Channel One.
“Phase one is over, the drug is safe and well tolerated. And the second phase has already begun on patients with a covid, “she said. Skvortsova added that after the second phase of clinical trials, it will be possible to start registering the drug.
FMBA plans to register the drug by the end of summer.
“We think that in the first stage the drug will not be in pharmacies, but… will be in medical organizations, “she said.
Earlier, the fact that scientists went to the second stage of testing the drug was reported by Izvestia. It is assumed that MIR-19 will be used in the inhalation form of administration by a nebulizer – so that the active substance will enter the cells of the respiratory tract, which are the main target of the virus.